Canine influenza is also known as dog flu, and it is a contagious respiratory disease that spreads in an airborne and aerosolized manner in dogs, caused by Type A influenza viruses. Till date, no human infections with canine influenza have been reported. Canine influenza is done in two segments are H3N8 virus and H3N2 (seasonal influenza A) virus. Canine influenza of H3N8 viruses done in horses spread to dogs and spread among dogs. The canine influenza H3N8 virus was first reported in 2004 in the U.S. Canine influenza of H3N2 viruses observed in birds spread to dogs and spread among dogs. The canine influenza H3N2 virus was first reported in 2007 in South Korea, and also have been reported in dogs in Canada, China, and Thailand. H3N2 canine influenza viruses were first reported in the United States in 2015, and are now found in more than 30 states of America. In 2016, for canine influenza treatment, Centers for Disease Control and Prevention (CDC) used the Influenza Risk Assessment Tool to analyze the risk of canine influenza H3N2 viruses, and found it to be very low. Broad spectrum antibiotics can be prescribed by a veterinarian if a bacterial infection is suspected, and intravenous fluids can be given to maintain hydration for canine influenza treatment. The U.S. Department of Agriculture (USDA) granted a conditional license to Zoetis in November 2015 for the first commercially available for canine influenza treatment as a canine influenza H3N2 vaccine and Merck Animal Health publicize the procurable of an H3N2 canine influenza vaccine. Still, there are no vaccines which have been approved for canine influenza treatment in cats.
Canine Influenza Treatment Market: Drivers and Restraints
The growing number of incidences of canine influenza is driving the growth of the market. Rapid turnaround time and lower cost of procedure as compared to conventional methods also fueling the growth of the canine influenza treatment market. Pet adoption and reimbursement processes are also available in many regions like the U.S. and Europe. However, the global market for canine influenza treatment is expected to be deterred by a limited number of vaccines available in the market, and increasing revenue in canine influenza treatment market. Also, the rise in FDA and research institutes’ approvals for canine influenza treatment is driving the canine influenza treatment market.
Canine Influenza Treatment Market: Segmentation
Tentatively, the canine influenza treatment market has been segmented on the basis of drug class and distribution channel.
Based on drug class, the canine influenza treatment market is segmented as:
- Nonsteroidal anti-inflammatory Drugs (NSAIDs)
- Antiviral Drugs
Based on distribution channel, the canine influenza treatment market is segmented as:
- Veterinary Clinics
- Veterinary Pharmacies
- Online Pharmacies
Canine Influenza Treatment Market: Overview
Asia has been severe with regards to the canine influenza virus. Canine influenza treatment in Korea, only one of the 5 dogs seen at 3 veterinary clinics survived. Likewise, 2 of 4 cases in pet dogs diagnosed in China were fatal. Approximately out of 200 dogs, 50 cats showed signs of respiratory disease. The morbidity rate in this outbreak was 100% in cats. In dogs, the fatality rate was 25%, and it was 40% in cats. In South Korean, animal shelter the morbidity and mortality rates were reported to be 77% and 23% in dogs, respectively, and 47% and 22%, respectively, in cats. Currently, the fatality rate in the U.S. appears to be low with regards to canine influenza treatment. News reports in May 2015 indicated that, there were approximately 8 deaths because of the virus among more than 1,500 cases. Respiratory disease was reported at 14 tracks in 6 states (Alabama, Arkansas, Florida, Kansas, Texas, and West Virginia), and 20 tracks in 11 states (Arizona, Arkansas, Colorado, Florida, Iowa, Kansas, Massachusetts, Rhode Island, Texas, West Virginia, and Wisconsin). The infection has also been confirmed in pet dogs in different states of America. Canine influenza treatment can be done in animal shelters, humane societies, pet stores, boarding kennels, and veterinary clinics. The increasing number of patient visits for canine influenza treatment and the growing demand for canine influenza treatment exhibits lucrative growth opportunities for the companies investing in the market.
Canine Influenza Treatment Market: Regional Outlook
Geographically, the canine influenza treatment market is segmented into regions, viz. North America, Europe, and Asia Pacific excluding Japan, and Middle East and Africa. North America and Europe exhibit healthy growth in terms of revenue, due to increased awareness of conducted canine influenza as a part of the routine check. The lower cost of the procedure as compared to other alternative treatments and low risk associated with the procedure is boosting the growth of the canine influenza treatment market. The developing cluster of the U.S and Asia is likely to gain momentum in late 2020.
Canine Influenza Treatment Market: Key Players
Some of the players identified in the canine influenza treatment market include Zoetis Inc., Merck Animal Health, GlaxoSmithKline Plc., Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Pfizer Inc., Boehringer Ingelheim International GmbH, Sanofi, Abbott Laboratories, and F. Hoffmann-La Roche Ltd.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors, along with market attractiveness as per segment. The report also maps the qualitative impact of various market factors on market segments and geographies.
The report covers an exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved
- Value Chain
Regional analysis includes
- North America (U.S., Canada) Canine Influenza Treatment Market
- Latin America ( Brazil, Mexico, Argentina, Chile, Peru, Rest of LATAM) Canine Influenza Treatment Market
- Europe (Germany, Italy, UK, Spain, France, Russia, Belgium, Netherlands, Luxemburg, Norway, Denmark, Iceland, Sweden, Poland, Ukraine, Czech Rep, Rest of Europe) Canine Influenza Treatment Market
- Asia Pacific Excluding Japan (India, Australia & New Zealand, Greater China, S. Korea, ASEAN Countries, Rest of APEJ) Canine Influenza Treatment Market
- Japan Canine Influenza Treatment Market
- CIS & Russia Canine Influenza Treatment Market
- Middle East and Africa (GCC, Turkey, Iran, Israel, South Africa, Rest Of MEA) Canine Influenza Treatment Market
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Benefits of Becoming a Fact.MR Client
- Access to our global market coverage
- Periodic updates on your sector
- Exclusive discounts and offers
- Greater flexibility for customization
- Quick-research assistance for ad-hoc needs
- Access to credible insights Fact.MR analyst interactions
- Access to Fact.MR tools and research to fuel strategy development